Liquid biopsies in gastrointestinal malignancies: when is the big day?

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623–631.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–361.
   PubMed Web of Science ®Google Scholar
• Pantel K, Deneve E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58(5):936–940.
   PubMed Web of Science ®Google Scholar
• Grover PK, Cummins AG, Price TJ, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol. 2014;25(8):1506–1516.
   PubMed Web of Science ®Google Scholar
• Kowalik A, Kowalewska M, Gozdz S. Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. Transl Res. 2017.
   PubMed Web of Science ®Google Scholar
• Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–3046.
   PubMed Web of Science ®Google Scholar
• Gerges N, Rak J, Jabado N. New technologies for the detection of circulating tumour cells. Br Med Bull. 2010;94:49–64.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang S, Fang Y, et al. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application. Oncotarget. 2017;8(2):3029–3041. Epub 2016/ 12/10.
   PubMed Web of Science ®Google Scholar
• Ao Z, Liu X. Fiber-Optic Array Scanning Technology (FAST) for detection and molecular characterization of circulating tumor cells. Methods Mol Biol. 2017;1634: 235–246. Epub 2017/ 08/19.
   PubMedGoogle Scholar
• Eliasova P, Pinkas M, Kolostova K, et al. Circulating tumor cells in different stages of colorectal cancer. Folia Histochemica et Cytobiologica. 2017;55(1): 1–5. Epub 2017/ 05/17.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
   PubMed Web of Science ®Google Scholar
• Hagland HR, Lea D, Watson MM, et al. Correlation of Blood T-cells to intratumoural density and location of CD3+ and CD8+ T-cells in colorectal cancer. Anticancer Res. 2017;37(2):675–683.
   PubMed Web of Science ®Google Scholar
• Won EJ, Ju JK, Cho YN, et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget. 2016;7(46):76274–76290.
   PubMed Web of Science ®Google Scholar
• Zhong F, Cui D, Tao H, et al. IL-17A-producing T cells and associated cytokines are involved in the progression of gastric cancer. Oncol Rep. 2015;34(5):2365–2374.
   PubMed Web of Science ®Google Scholar
• Hayakawa S, Okada S, Tsumura M, et al. A patient with CTLA-4 haploinsufficiency presenting gastric cancer. J Clin Immunol. 2016;36(1):28–32.
   PubMed Web of Science ®Google Scholar
• Swaminathan R, Butt AN. Circulating nucleic acids in plasma and serum: recent developments. Ann N Y Acad Sci. 2006;1075:1–9.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra54.
   Web of Science ®Google Scholar
• Howell JA, Khan SA, Knapp S, et al. The clinical role of circulating free tumor DNA in gastrointestinal malignancy. Transl Res. 2017;183:137–154.
   PubMed Web of Science ®Google Scholar
• Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2(20):20ra14.
   PubMed Web of Science ®Google Scholar
• https://www.aacc.org.
   Google Scholar
• Toth K, Bartak BK, Tulassay Z, et al. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis. Expert Rev Mol Diagn. 2016;16(2):239–252.
   PubMed Web of Science ®Google Scholar
• Best MG, Sol N, Kooi I, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. 2015;28(5):666–676.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714.
   PubMed Web of Science ®Google Scholar
• Huntley RP, Sitnikov D, Orlic-Milacic M, et al. Guidelines for the functional annotation of microRNAs using the gene ontology. RNA. 2016;22(5):667–676.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–335.
   PubMed Web of Science ®Google Scholar
• Cyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. Am J Manag Care. 2016;22(2):105–111.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Danese E, Montagnana M, Minicozzi AM, et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med. 2010;48(11):1665–1668.
   PubMed Web of Science ®Google Scholar
• Hao TB, Shi W, Shen XJ, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111(8):1482–1489.
   PubMed Web of Science ®Google Scholar
• Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–325.
   PubMed Web of Science ®Google Scholar
• Roperch JP, Incitti R, Forbin S, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13:566.
   PubMed Web of Science ®Google Scholar
• Toth K, Sipos F, Kalmar A, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One. 2012;7(9):e46000.
   PubMed Web of Science ®Google Scholar
• Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15(19):6185–6191.
   PubMed Web of Science ®Google Scholar
• deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55(7):1337–1346.
   PubMed Web of Science ®Google Scholar
• Scott M, McCluggage WG, Hillan KJ, et al. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer. 2006;118(5):1325–1329.
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441–50, W81.
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142(2):248–256. quiz e25-6.
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297.
   PubMed Web of Science ®Google Scholar
• Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100–121.
   PubMed Web of Science ®Google Scholar
• Guo Y, Bao Y, Yang W. Regulatory miRNAs in colorectal carcinogenesis and metastasis. Int J Mol Sci. 2017;18(4).
   Web of Science ®Google Scholar
• Carter JV, Galbraith NJ, Yang D, et al. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2017;116(6):762–774.
   PubMed Web of Science ®Google Scholar
• Zheng G, Du L, Yang X, et al. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer. 2014;111(10):1985–1992. Epub 2014/ 09/19.
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Roberts H, Eichenberger MR, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013;258(3):400–408. Epub 2013/ 09/12.
   PubMed Web of Science ®Google Scholar
• Luo X, Stock C, Burwinkel B, et al. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One. 2013;8(5): e62880. Epub 2013/ 05/22.
   PubMed Web of Science ®Google Scholar
• Wang S, Xiang J, Li Z, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2015;136(1):152–161. Epub 2013/ 03/05.
   PubMed Web of Science ®Google Scholar
• Vychytilova-Faltejskova P, Radova L, Sachlova M, et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis. 2016;37(10):941–950. Epub 2016/ 08/04.
   PubMed Web of Science ®Google Scholar
• Ren D, Lin B, Zhang X, et al. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget. 2017;8(30):49807–49823. Epub 2017/ 06/08.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016;7(51):85551–85563. Epub 2016/ 11/27.
   PubMed Web of Science ®Google Scholar
• Zhu M, Huang Z, Zhu D, et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget. 2017;8(10):17081–17091. Epub 2017/ 02/09.
   PubMed Web of Science ®Google Scholar
• Mahalingam J, Lin CY, Chiang JM, et al. CD4(+) T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer. PLoS One. 2014;9(9):e108554.
   PubMed Web of Science ®Google Scholar
• Xu B, Yuan L, Gao Q, et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget. 2015;6(24):20592–20603. Epub 2015/ 05/27.
   PubMed Web of Science ®Google Scholar
• Lee JY, Seo EH, Oh CS, et al. Impact of circulating T helper 1 and 17 cells in the blood on regional lymph node invasion in colorectal cancer. J Cancer. 2017;8(7):1249–1254. Epub 2017/ 06/14.
   PubMed Web of Science ®Google Scholar
• Zhu CB, Wang CX, Zhang X, et al. Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer. 2011;128(3):617–622.
   PubMed Web of Science ®Google Scholar
• Cao M, Yie SM, Liu J, et al. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011;78(2):120–128.
   PubMed Web of Science ®Google Scholar
• Reinert T, Scholer LV, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65(4):625–634.
   PubMed Web of Science ®Google Scholar
• Tsai WS, Chen JS, Shao HJ, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep. 2016;6:24517.
   PubMed Web of Science ®Google Scholar
• Hinz S, Hendricks A, Wittig A, et al. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study. BMC Cancer. 2017;17(1):53.
   PubMed Web of Science ®Google Scholar
• Bork U, Rahbari NN, Scholch S, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112(8):1306–1313.
   PubMed Web of Science ®Google Scholar
• Sotelo MJ, Sastre J, Maestro ML, et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015;26(3):535–541.
   PubMed Web of Science ®Google Scholar
• Seeberg LT, Waage A, Brunborg C, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg. 2015;261(1):164–171.
   PubMed Web of Science ®Google Scholar
• Musella V, Pietrantonio F, Di Buduo E, et al. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer. 2015;137(6):1467–1474.
   PubMed Web of Science ®Google Scholar
• van Dalum G, Stam GJ, Scholten LF, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46(3):1361–1368.
   PubMed Web of Science ®Google Scholar
• Kuboki Y, Matsusaka S, Minowa S, et al. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013;33(9):3905–3910.
   PubMed Web of Science ®Google Scholar
• Sastre J, Maestro ML, Gomez-Espana A, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 2012;17(7):947–955.
   PubMed Web of Science ®Google Scholar
• Matsusaka S, Suenaga M, Mishima Y, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2011;102(6):1188–1192.
   PubMed Web of Science ®Google Scholar
• Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 2011;29(12):1547–1555.
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006–1012.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–3221.
   PubMed Web of Science ®Google Scholar
• Bedin C, Enzo MV, Del Bianco P, et al. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer. 2017;140(8):1888–1898.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Appelt AL, Pallisgaard N, et al. DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 2014;135(12):2984–2991.
   PubMed Web of Science ®Google Scholar
• Lin JK, Lin PC, Lin CH, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21(Suppl 4):S680–6.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chew MH, Tham CK, et al. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am J Cancer Res. 2016;6(9):2098–2108.
   PubMed Web of Science ®Google Scholar
• Tham C, Chew M, Soong R, et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer. 2014;120(20):3131–3141.
   PubMed Web of Science ®Google Scholar
• Philipp AB, Stieber P, Nagel D, et al. Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer. 2012;131(10):2308–2319.
   PubMed Web of Science ®Google Scholar
• Vymetalkova V, Pardini B, Rosa F, et al. Polymorphisms in microRNA binding sites of mucin genes as predictors of clinical outcome in colorectal cancer patients. Carcinogenesis. 2017;38(1):28–39.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Hur K, Tanaka K, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–743.
   PubMed Web of Science ®Google Scholar
• Kjersem JB, Ikdahl T, Lingjaerde OC, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014;8(1):59–67.
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–859.
   PubMedGoogle Scholar
• Liu GH, Zhou ZG, Chen R, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34(4):2175–2181.
   PubMedGoogle Scholar
• Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–1726. Epub 2010/ 01/27.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang HY, Li J, et al. The elevated NLR, PLR and PLT May predict the prognosis of patients with colorectal cancer: a systematic review and metaanalysis. Oncotarget. 2017;8:68837-68846.
   Google Scholar
• Overman MJ, Vauthey J-N, Aloia, TA, et al. Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol. 2017; 35:15_suppl, 3522-3522.
   Google Scholar
• Tsukamoto M, Iinuma H, Yagi T, et al. Circulating exosomal MicroRNA-21 as a biomarker in each tumor stage of colorectal cancer. Oncology. 2017;92(6): 360–370. Epub 2017/ 04/05.
   PubMed Web of Science ®Google Scholar
• Matsumura T, Sugimachi K, Iinuma H, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113(2):275–281. Epub 2015/ 06/10.
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Weiner LM, Marshall JL, et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One. 2014;9(1):e84686. Epub 2014/ 01/09.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430–435.
   PubMed Web of Science ®Google Scholar
• Saunders MP, Cooney C, Edelstein D, et al. Performance assessment of blood based RAS mutation testing: concordance of results obtained from prospectively collected samples. Ann Oncol. 2016;27(suppl_6):526P.
   PubMed Web of Science ®Google Scholar
• Vidal Barrull J, Muinelo Romay J, Dalmases A, et al. Accuracy of plasma RAS mutation testing for therapy selection and monitoring of colorectal cancer patients. Ann Oncol. 2016;27(suppl_6):533P.
   Google Scholar
• Bachet J-B, Bouche O, Taieb J, et al. RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study. J Clin Oncol. 2017;35(no.15_suppl):11509.
   Web of Science ®Google Scholar
• Diaz LA Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540.
   PubMed Web of Science ®Google Scholar
• Morelli MP, Overman MJ, Dasari A, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26(4):731–736.
   PubMed Web of Science ®Google Scholar
• Matikas A, Voutsina A, Lagoudaki E, et al. Detection of KRAS Exon 2 mutations in circulating tumor cells isolated by the ISET system from patients with RAS wild type metastatic colorectal cancer. Transl Oncol. 2017;10(4):693–698. Epub 2017/ 07/12.
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801.
   PubMed Web of Science ®Google Scholar
• Garlan F, Laurent-Puig P, Sefrioui D, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res. 2017.
   Web of Science ®Google Scholar
• Kitahara M, Hazama S, Tsunedomi R, et al. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci. 2016;107(12):1825–1829.
   PubMed Web of Science ®Google Scholar
• Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715–1722.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–948.
   PubMed Web of Science ®Google Scholar
• Spindler KL, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18(4):1177–1185.
   PubMed Web of Science ®Google Scholar
• Herbst A, Vdovin N, Gacesa S, et al. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. Int J Cancer. 2017;140(9):2134–2144.
   PubMed Web of Science ®Google Scholar
• Hansen TF, Carlsen AL, Heegaard NH, et al. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015;112(4):624–629.
   PubMed Web of Science ®Google Scholar
• Huang X, Gao P, Song Y, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. BMC Cancer. 2015;15:202, Epub 2015/ 04/17.
   PubMed Web of Science ®Google Scholar
• Magni E, Botteri E, Ravenda PS, et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis. 2014;29(9):1053–1059.
   PubMed Web of Science ®Google Scholar
• Pucciarelli S, Rampazzo E, Briarava M, et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2012;19(9):3089–3096.
   PubMed Web of Science ®Google Scholar
• Tada N, Kawai K, Tsuno NH, et al. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol. 2015;13:30, Epub 2015/ 04/19.
   PubMed Web of Science ®Google Scholar
• Schmidt MA, Fortsch C, M S, et al. Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment. Radiother Oncol. 2012;104(1): 131–138. Epub 2012/ 06/12.
   PubMed Web of Science ®Google Scholar
• Hinz S, Roder C, Tepel J, et al. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer. 2015;15:953.
   PubMed Web of Science ®Google Scholar
• Tang L, Zhao S, Liu W, et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer. 2013;13:314.
   PubMed Web of Science ®Google Scholar
• Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119(22):3984–3991.
   PubMed Web of Science ®Google Scholar
• Okabe H, Tsunoda S, Hosogi H, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22(12):3954–3961.
   PubMed Web of Science ®Google Scholar
• Li Y, Gong J, Zhang Q, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016;114(2):138–145.
   PubMed Web of Science ®Google Scholar
• Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86(3):136–142.
   PubMed Web of Science ®Google Scholar
• Han J, Lv P, Yu JL, et al. Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer. Dig Dis Sci. 2014;59(6):1160–1168.
   PubMed Web of Science ®Google Scholar
• Ling ZQ, Lv P, Lu XX, et al. Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer. PLoS One. 2013;8(6):e67195.
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Chu ES, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 2005;92(12):2190–2194.
   PubMed Web of Science ®Google Scholar
• Zou B, Chim CS, Zeng H, et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 2006;131(6):1835–1843.
   PubMed Web of Science ®Google Scholar
• Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;110(9):2291–2299.
   PubMed Web of Science ®Google Scholar
• Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7(7):e41629.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47(5):784–791.
   PubMed Web of Science ®Google Scholar
• Wang N, Wang L, Yang Y, et al. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochem Biophys Res Commun. 2017;493(3): 1322–1328. Epub 2017/ 10/08.
   PubMed Web of Science ®Google Scholar
• Cui L, Zhang X, Ye G, et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119(9):1618–1626.
   PubMed Web of Science ®Google Scholar
• Saito H, Yamada Y, Takaya S, et al. Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer. Surg Today. 2015;45(11):1429–1435.
   PubMed Web of Science ®Google Scholar
• Dong L, Qi P, Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015;137(5):1128–1135.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yin C, Dang Y, et al. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5:11516.
   PubMed Web of Science ®Google Scholar
• Shao Y, Ye M, Jiang X, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer. 2014;120(21):3320–3328.
   PubMed Web of Science ®Google Scholar
• Li Q, Shao Y, Zhang X, et al. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 2015;36(3):2007–2012. Epub 2014/11/14.
   PubMed Web of Science ®Google Scholar
• Huang Y, Liao H, Zhang Y, et al. Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS One. 2014;9(5):e94376.
   PubMed Web of Science ®Google Scholar
• Mizrak Kaya D, Harada K, Shimodaira Y, et al. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017;10(3):263–271.
   PubMed Web of Science ®Google Scholar
• Cardoso R, Coburn NG, Seevaratnam R, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15(Suppl 1):S164–7.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, De Groot JW, Los M, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: a multicenter phase 2 study. Cancer. 2016;122(9):1434–1443.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee J, Kim ST, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Markers. 2015;30(4):e382–6.
   PubMed Web of Science ®Google Scholar
• Imaoka H, Toiyama Y, Okigami M, et al. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 2016;19(3):744–753.
   PubMed Web of Science ®Google Scholar
• Huang D, Wang H, Liu R, et al. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2014;115(3):549–556.
   PubMed Web of Science ®Google Scholar
• Chen Q, Ge X, Zhang Y, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 2014;31(4):1863–1870.
   PubMed Web of Science ®Google Scholar
• Fu Z, Qian F, Yang X, et al. Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. Med Oncol. 2014;31(9):164.
   PubMed Web of Science ®Google Scholar
• Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep. 2012;5(6):1514–1520.
   PubMed Web of Science ®Google Scholar
• Zou K, Yang S, Zheng L, et al. Prognostic role of the circulating tumor cells detected by cytological methods in gastric cancer: a meta-analysis. Biomed Res Int. 2016;2016: 2765464. Epub 2016/ 11/16.
   PubMed Web of Science ®Google Scholar
• Jiang C, Chen X, Alattar M, et al. MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. Cancer Gene Ther. 2015;22(6):291–301.
   PubMed Web of Science ®Google Scholar
• Liu T, Tang H, Lang Y, et al. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009;273(2):233–242.
   PubMed Web of Science ®Google Scholar
• Sun J, Chen X, Gao P, et al. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. Dis Markers. 2016;2016:7862469.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang H, Zang W, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Sci. 2017;108:1881-1887.
   Web of Science ®Google Scholar
• Kubisch I, De Albuquerque A, Schuppan D, et al. Prognostic role of a multimarker analysis of circulating tumor cells in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2015;89(5):294–303.
   PubMed Web of Science ®Google Scholar
• Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15(11):3092–3100.
   PubMed Web of Science ®Google Scholar
• Kaganoi J, Shimada Y, Kano M, et al. Detection of circulating oesophageal squamous cancer cells in peripheral blood and its impact on prognosis. Br J Surg. 2004;91(8):1055–1060.
   PubMed Web of Science ®Google Scholar
• Takeshita N, Hoshino I, Mori M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013;108(3):644–652.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wen W, Zhu J, et al. A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget. 2017;8:34468-34480.
   Web of Science ®Google Scholar
• Huang Z, Zhang L, Zhu D, et al. A novel serum microRNA signature to screen esophageal squamous cell carcinoma. Cancer Med. 2017;6(1):109–119.
   PubMed Web of Science ®Google Scholar
• Chiam K, Wang T, Watson DI, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg. 2015;19(7):1208–1215.
   PubMed Web of Science ®Google Scholar
• Li SP, Guan QL, Zhao D, et al. Detection of circulating tumor cells by fluorescent immunohistochemistry in patients with esophageal squamous cell carcinoma: potential clinical applications. Med Sci Monit. 2016;22:1654–1662.
   PubMed Web of Science ®Google Scholar
• Reeh M, Effenberger KE, Koenig AM, et al. Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer. Ann Surg. 2015;261(6):1124–1130.
   PubMed Web of Science ®Google Scholar
• Matsushita D, Uenosono Y, Arigami T, et al. Clinical significance of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22(11):3674–3680.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yano M, Motoori M, et al. CEA-antigen and SCC-antigen mRNA expression in peripheral blood predict hematogenous recurrence after resection in patients with esophageal cancer. Ann Surg Oncol. 2010;17(10):2779–2786.
   PubMed Web of Science ®Google Scholar
• Ling ZQ, Zhao Q, Zhou SL, et al. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2012;38(4):326–332.
   PubMed Web of Science ®Google Scholar
• Faluyi OO, Eng L, Qiu X, et al. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Med. 2017;6(2):361–373.
   PubMed Web of Science ®Google Scholar
• Li SP, Su HX, Zhao D, et al. Plasma miRNA-506 as a prognostic biomarker for esophageal squamous cell carcinoma. Med Sci Monit. 2016;22:2195–2201.
   PubMed Web of Science ®Google Scholar
• Yang X, Huang Y, Feng JF, et al. Prognostic significance of neutrophil-to- lymphocyte ratio in esophageal cancer: a meta-analysis. Onco Targets Ther. 2015;8:789–794.
   PubMed Web of Science ®Google Scholar
• Nozoe T, Maehara Y, Sugimachi K. Preoperative sorting of circulating T lymphocytes in patients with esophageal squamous cell carcinoma: its prognostic significance. World J Gastroenterol. 2005;11(42): 6689–6693. Epub 2006/ 01/21.
   PubMed Web of Science ®Google Scholar
• Wang S, Du H, Li G. Significant prognostic value of circulating tumor cells in esophageal cancer patients: a meta-analysis. Oncotarget. 2017;8(9): 15815–15826. Epub 2017/ 02/09.
   PubMed Web of Science ®Google Scholar
• Ge C, Wu S, Wang W, et al. miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/beta-catenin signalling pathway. Oncotarget. 2015;6(13):10964–10977.
   PubMed Web of Science ®Google Scholar
• Yin XD, Yuan X, Xue JJ, et al. Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy. Dis Esophagus. 2012;25(8):750–756.
   PubMed Web of Science ®Google Scholar
• Dong W, Li B, Wang J, et al. Diagnostic and predictive significance of serum microRNA-7 in esophageal squamous cell carcinoma. Oncol Rep. 2016;35(3):1449–1456.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Miyata H, Sugimura K, et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis. 2015;36(8):894–903.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Miyata H, Yamasaki M, et al. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol. 2013;20(Suppl 3):S607–15.
   PubMed Web of Science ®Google Scholar
• Yu H, Duan B, Jiang L, et al. Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res. 2013;6(1):71–77.
   PubMed Web of Science ®Google Scholar
• Prislei S, Martinelli E, Mariani M, et al. MiR-200c and HuR in ovarian cancer. BMC Cancer. 2013;13:72.
   PubMed Web of Science ®Google Scholar
• Yu Q, Li B, Li P, et al. Plasma microRNAs to predict the response of radiotherapy in esophageal squamous cell carcinoma patients. Am J Transl Res. 2015;7(10):2060–2071.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73(10):2965–2975.
   PubMed Web of Science ®Google Scholar
• Zill OA, Mortimer S, Banks, KC, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. J Clin Oncol. 2016;34(18):_suppl.LBA11501.
   Web of Science ®Google Scholar
• Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483–3489.
   PubMed Web of Science ®Google Scholar
• Yu KH, Ricigliano M, Hidalgo M, et al. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res. 2014;20(20):5281–5289.
   PubMed Web of Science ®Google Scholar
• Grossman RL, Abel B, Angiuoli S, et al. Collaborating to compete: Blood Profiling Atlas in Cancer (BloodPAC) consortium. Clin Pharmacol Ther. 2017;101(5):589–592.
   PubMed Web of Science ®Google Scholar